8-KOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Jan 16, 2025)

Filed January 16, 2025For Securities:BSX

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report on January 16, 2025, announcing a significant development in pending shareholder derivative actions. The report details that on January 8, 2025, the United States District Court for the District of Massachusetts granted preliminary approval to a proposed settlement concerning two shareholder derivative lawsuits and demands for company records. These actions are directly related to the prior recall and retirement of the LOTUS Edge™ Aortic Valve System. The proposed settlement, agreed upon by various parties including the company and named defendants, is now subject to final court approval. A hearing for this final approval is scheduled for March 25, 2025. Investors should monitor this date as it will determine the final resolution of these legal matters and any potential implications for the company.

Key Highlights

  • 1Preliminary court approval granted for a settlement of shareholder derivative actions.
  • 2The lawsuits are related to the recall and retirement of the LOTUS Edge™ Aortic Valve System.
  • 3A final court approval hearing is scheduled for March 25, 2025.
  • 4The company is filing the Stipulation of Settlement and Notice of Proposed Derivative Settlement as exhibits.
  • 5This filing indicates a potential resolution to ongoing legal proceedings stemming from a past product issue.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform investors that the United States District Court for the District of Massachusetts has granted preliminary approval to a settlement of two shareholder derivative lawsuits and demands for company records related to the LOTUS Edge™ Aortic Valve System recall.

The lawsuits are shareholder derivative actions and demands for access to company records that arose from the prior recall and retirement of the LOTUS Edge™ Aortic Valve System.

The next key step is a court hearing scheduled for March 25, 2025, where the Court will determine whether to grant final approval to the proposed settlement.

The filing itself does not specify the financial terms of the settlement or its impact on Boston Scientific's financials. The details of the settlement are contained within the Stipulation and Agreement of Settlement (Exhibit 99.1), which would require further review to ascertain any financial implications.